MEDICINES CO /DE Form 8-K April 19, 2006

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

**WASHINGTON D.C. 20549** 

# FORM 8-K

## **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): April 19, 2006

# **The Medicines Company**

(Exact Name of Registrant as Specified in Charter)

**Delaware** (State or Other Jurisdiction of Incorporation) **000-31191** (Commission File Number)

**04-3324394** (IRS Employer Identification No.)

8 Campus Drive
Parsippany, New Jersey
(Address of Principal Executive Offices)


07054

(Zip Code)

Registrant s telephone number, including area code: (973) 656-1616

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):



T4 3	02 D.	14 C O	4		1 /	7 1.4
item 2.	uz. Kesi	uits of Or	eramons a	ana rinai	ıcıaı (	Condition.

On April 19, 2006, The Medicines Company (the Company ) announced financial results for the quarter ended March 31, 2006. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act ) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

#### Item 9.01. Financial Statements and Exhibits

(c) Exhibits

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:

99.1 Press release dated April 19, 2006 entitled The Medicines Company Reports First Quarter 2006 Financial Results

2

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

## THE MEDICINES COMPANY

Date: April 19, 2006 By: /s/ Glenn P. Sblendorio

Glenn P. Sblendorio

Executive Vice President and Chief Financial Officer

3

## **Exhibit Index**

Exhibit No.	Description				
99.1	Press release dated April 19, 2006 entitled	The Medicines Company Reports First Quarter 2006 Financial Results			

4